AU733646B2 - Preparation of crystal form II of clarithromycin - Google Patents

Preparation of crystal form II of clarithromycin Download PDF

Info

Publication number
AU733646B2
AU733646B2 AU37405/97A AU3740597A AU733646B2 AU 733646 B2 AU733646 B2 AU 733646B2 AU 37405/97 A AU37405/97 A AU 37405/97A AU 3740597 A AU3740597 A AU 3740597A AU 733646 B2 AU733646 B2 AU 733646B2
Authority
AU
Australia
Prior art keywords
carbon atoms
methylerythromycin
solvent
alkanol
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU37405/97A
Other languages
English (en)
Other versions
AU3740597A (en
Inventor
Jih-Hua Liu
David A. Riley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BGP Products Operations GmbH
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27102712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU733646(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/681,695 external-priority patent/US5844105A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of AU3740597A publication Critical patent/AU3740597A/en
Application granted granted Critical
Publication of AU733646B2 publication Critical patent/AU733646B2/en
Assigned to BGP PRODUCTS OPERATIONS GMBH reassignment BGP PRODUCTS OPERATIONS GMBH Alteration of Name(s) in Register under S187 Assignors: ABBOTT LABORATORIES
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU37405/97A 1996-07-29 1997-07-28 Preparation of crystal form II of clarithromycin Expired AU733646B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/681,695 US5844105A (en) 1996-07-29 1996-07-29 Preparation of crystal form II of clarithromycin
US08/681695 1996-07-29
US90027197A 1997-07-25 1997-07-25
US08/900271 1997-07-25
PCT/US1997/013166 WO1998004574A1 (en) 1996-07-29 1997-07-28 Preparation of crystal form ii of clarithromycin

Publications (2)

Publication Number Publication Date
AU3740597A AU3740597A (en) 1998-02-20
AU733646B2 true AU733646B2 (en) 2001-05-17

Family

ID=27102712

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37405/97A Expired AU733646B2 (en) 1996-07-29 1997-07-28 Preparation of crystal form II of clarithromycin

Country Status (12)

Country Link
EP (1) EP0915899B1 (cg-RX-API-DMAC7.html)
JP (4) JP4104660B2 (cg-RX-API-DMAC7.html)
KR (1) KR100524214B1 (cg-RX-API-DMAC7.html)
AT (1) ATE272646T1 (cg-RX-API-DMAC7.html)
AU (1) AU733646B2 (cg-RX-API-DMAC7.html)
CA (1) CA2261732C (cg-RX-API-DMAC7.html)
DE (3) DE69730138T2 (cg-RX-API-DMAC7.html)
DK (1) DK0915899T3 (cg-RX-API-DMAC7.html)
ES (1) ES2173057T3 (cg-RX-API-DMAC7.html)
IL (1) IL127833A (cg-RX-API-DMAC7.html)
PT (1) PT915899E (cg-RX-API-DMAC7.html)
WO (1) WO1998004574A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US6245903B1 (en) 1998-08-21 2001-06-12 Apotex, Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR20010008496A (ko) * 1999-07-01 2001-02-05 유충식 6-오-메틸 에리트로마이신의 제조방법
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
CZ20021999A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV
CA2397092A1 (en) * 2000-01-11 2001-07-19 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
WO2001064224A1 (en) 2000-02-29 2001-09-07 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
KR100361397B1 (ko) * 2000-03-15 2002-11-23 한미약품공업 주식회사 에리스로마이신 에이 9-오-트로필옥심 유도체를 이용한클라리스로마이신의 제조방법
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
DE60122791T2 (de) * 2000-03-15 2007-10-04 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von Clarythromycin mit nicht pharmazeutischer Qualität
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
DE60209704T2 (de) 2001-05-22 2006-11-16 Pfizer Products Inc., Groton Neue kristallforme von azithromycin
US6861413B2 (en) 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1652851A1 (en) * 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
KR100372254B1 (en) * 2002-07-15 2003-02-19 Korea United Pharm Inc Erythromycin a 9-o-pseudosaccharinyl oxime derivative and process for preparing clarithromycin using the same
EP1435359A1 (en) * 2002-12-31 2004-07-07 Alembic Limited A process for the purification of roxithromycin
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
MX2009005977A (es) * 2006-12-05 2009-06-17 Pfizer Polimorfos de motilida.
DE102007016367A1 (de) * 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4672109A (en) * 1984-04-06 1987-06-09 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin A derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS572298A (en) * 1980-06-04 1982-01-07 Taisho Pharmaceut Co Ltd Erythromycin derivative
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
JP2782793B2 (ja) * 1988-06-15 1998-08-06 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
ZA922776B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical compounds
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4672109A (en) * 1984-04-06 1987-06-09 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin A derivatives

Also Published As

Publication number Publication date
DE29724846U1 (de) 2004-12-16
CA2261732A1 (en) 1998-02-05
DE69730138D1 (de) 2004-09-30
JP2006137765A (ja) 2006-06-01
KR100524214B1 (ko) 2005-11-01
KR20000029591A (ko) 2000-05-25
JP2013151542A (ja) 2013-08-08
ES2173057T1 (es) 2002-10-16
DE97934319T1 (de) 2004-08-26
IL127833A0 (en) 1999-10-28
JP2009242411A (ja) 2009-10-22
ATE272646T1 (de) 2004-08-15
EP0915899A1 (en) 1999-05-19
CA2261732C (en) 2001-07-24
DE69730138T2 (de) 2005-03-03
WO1998004574A1 (en) 1998-02-05
DK0915899T3 (da) 2004-11-29
IL127833A (en) 2004-06-20
JP2002514171A (ja) 2002-05-14
PT915899E (pt) 2004-11-30
AU3740597A (en) 1998-02-20
ES2173057T3 (es) 2004-11-16
EP0915899B1 (en) 2004-08-04
JP4104660B2 (ja) 2008-06-18

Similar Documents

Publication Publication Date Title
US5844105A (en) Preparation of crystal form II of clarithromycin
EP0915899B1 (en) Preparation of crystal form ii of clarithromycin
US5858986A (en) Crystal form I of clarithromycin
CA2277274C (en) Crystal form 0 of clarithromycin
AU783055B2 (en) Processes for preparing clarithromycin polymorphs and novel polymorph IV
CA2386527C (en) Crystal form i of clarithromycin
AU777612B2 (en) Crystal form I of clarithromycin
CA2488397C (en) Crystal form ii of clarithromycin
CA2386534C (en) Crystal form ii of clarithromycin and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)